Company / Return on Equity (ROE)
Zentalis Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-135.2%
FY2025
5-year range
-135.2% / -70.2%
FY2024-FY2025
Trend
-92.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Zentalis Pharmaceuticals, Inc. reports negative total equity of -135.2% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-135.2% in FY2025.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 92.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -135.2% | -92.4% |
| FY2024 | -70.2% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026